Member Info for WeTookPelham

"The Company's auditor, BDO LLP, has requested additional time to complete their standard audit due to unforeseen circumstances impacting the audit engagement team. Scancell's Board has been advised that the audit is substantially complete and has not been advised of any material audit issues."

'Substantially complete' at least? Cutting it fine either way.

Don't fully understand audits but the implication is if not in by Tues close it's share suspension? As the poster says though 'Underlying reason is not material according to latest RNS' so no fault on Scancells side.

As per that posters comment and somewhere else I read it sounds like a potentially good trading opportunity to buy before a potential suspension and wait for it to re-open?

Indeed.

60 + staff and still need extra hands on deck for processing the trial samples. Encouraging IMO.

Https://jobs.newscientist.com/job/1401925321/associate-scientist-translational-research-oxford-/?LinkSource=TopJob

Ah I didn't see ICB888's post, their explanation says what I meant to say better.

Let's not forget the Genmab deal was done way before the idea of Scancell even having a Chief Business Officer. So clearly they was enough nous in the company previously to get deals of some kind done.

IMO Dr Semhi is a perhaps a big deal closer/finaliser?

"Dragon....personally...whatever it takes to get the SP elevated !"

This! Couldn't care less what the reason is. An unsubstantiated buyout rumour will do me.

Regarding Nasdaq listing, I don't think anyone replied to my question about the implications for us shareholders shirt, medium and long term?

Worth a read IMO:

https://investor.seagen.com/press-releases/news-details/2022/Seagen-Astellas-and-Merck-Announce-Results-of-Clinical-Trial-Investigating-PADCEV-enfortumab-vedotin-ejfv-with-KEYTRUDA-pembrolizumab-and-PADCEV-as-Monotherapy-in-First-Line-Advanced-Urothelial-Cancer/default.aspx

https://www.fiercepharma.com/pharma/esmo-seagen-astellas-and-merck-knock-it-out-park-padcev-keytruda-combo-bladder-cancer

https://www.oncologypipeline.com/apexonco/esmo-2023-daiichi-shows-why-merck-paid-2bn-cdh6

Top analysis as ever JB1.

Assuming this were to happen what are the potential short,medium and long term implications for shareholders?

Looks like it was published yesterday TF:

https://jitc.bmj.com/content/11/10/e006966.info

Https://jitc.bmj.com/content/11/10/e006966?rss=1

...taken advantage of the (second) overreaction to the second auditor delay with a 150k buy.

"....BDO has form on this...and more than once..."

Time for a new auditor I seems.

Not too unhappy though as I, and by the looks of it others, have used it as a cheeky top up opportunity.

To be fair you can't argue with the clarity of the RNS, stating exactly what is going on, Scancell in the past would have no doubt been vague about which would have caused uncertainty. Scancell have seen to have improved noticeably in this department.

TF Dr Semhi is a she.

I guess we agree to disagree Bojo.

Your argument falls over for me somewhat because of all the numerous pre-clinal/early phase deals that happen all the time. IMO.

Moonparty - you've absolutely nailed that reply. Very well said.

Also for those who seem to think deal/collaboration news is eons away, why are you invested here in the short/medium term? Surely your money is better invested elsewhere in the meantime if that's what you think?

Thanks ciaskin, and yes, indeed it does look almost like it was planned!

But I'm sure it's just a coincidence 😉

Can someone please remind me of the near term upcoming events/conferences itinerary for Scancell.

I think I'm getting them mixed up.

Also, have Scancell attended the World Vaccine Congress before?

Hi CW, who is Eep?

Correct link:

https://www.marketwatch.com/story/tempest-therapeutics-stock-jumps-1-900-as-liver-cancer-treatment-shows-promise-5ba57298

But an increase of two and bit months?

But even the UK market should have recognised the impact of those SCIB1 results more than it did, no?

It's bizarre IMO.